HAYWARD (KPIX 5) - We've combined smart drug delivery where we've timed the delivery of the nicotine to deal with the patients or the consumers cravings," Chrono Therapeutics, R&D Co-VP, Dr. Patrick Ruane said.
Alan Levy, PhD Chairman and Chief Executive Officer of Chrono Therapeutics, talks about Chrono Therapeutics and what makes the company and its platform worthy of the World Economic Forum's 2016 Technology Pioneer award.
Jenny Hapgood, Vice President of Marketing & Product Management at Chrono Therapeutics, discusses the future of personalized medicine and its application to smoking cessation at SXSW 2016.
Alan Levy, PhD Chairman and Chief Executive Officer of Chrono Therapeutics, talks about personalized drug delivery with Tim Reha of Digital Health LIVE.
Dr. Patrick Ruane, SVP of Research & Development, presented Chrono's clinical trial data at the SRNT Annual Conference 2016.
Chrono Therapeutics was featured in The MedTech Strategist, March 16, 2016, Vol. 3, No. 4.
In the news
Want to Quit Smoking? Biotech Startup Chrono Gets $48M for Drug/Behavioral Combo
Forbes, Sept 8, 2016
Biotech hasn’t come up with many innovative answers in the past two decades to one of the world’s toughest public health problems — smoking. Now a startup in the San Francisco Bay area is raising a bundle of cash to help smokers kick the habit with some carefully calibrated drug delivery and behavioral nudges.
Hayward, Calif.-based Chrono Therapeutics is announcing today it has raised $47.6 million in a Series B round of venture capital. The investment was led by Kaiser Permanente ngIf: ticker Ventures ...
six new medical technologies worth watching
The Wall Street Journal, Jun 26, 2016
From growing blood vessels in labs to applying advanced nanotechnology to cancer testing, here are some emerging technologies that could have a big impact on medicine in coming years.
Cigarette smoking causes one-fifth of U.S. deaths each year, but the most commonly used methods for quitting have spotty effectiveness. Harvard University researchers found in a 2012 study that nicotine gum and patches were no better than going cold turkey in helping smokers quit long term.
FROM 'WEARABLES TO THER-ABLES'
Drug Store News, Apr 14, 2016
Unit shipments for wearable devices were expected to drive about $32 billion in revenue by 2019 — more than three times the $10 billion in revenue the market saw in 2013, according to a 2015 IHS Technology white paper on the wearables market. Beside the business applications IHS identified, it also focused on consumer possibilities in the wearables market — as fitness trackers, health data collectors and beyond.
The potential that IHS identified is something that entrepreneurs are currently working on tapping into, and industry observers have taken note of the evolving role of wearables.
WEARABLE TRANSDERMAL DRUG DELIVERY DEVICE REDUCES NICOTINE CRAVINGS
Pharm Pro, Mar 4, 2016
Chrono Therapeutics announced that clinical data for the company's smoking cessation technology showed a statistically significant reduction in nicotine cravings in a trial of adult male smokers. The data were presented at the Society of Research on Nicotine & Tobacco's 22nd Annual Meeting.
Chrono's wearable transdermal drug delivery device times nicotine delivery to when smokers have their strongest cravings. For example, 75 percent of all smokers reach for their first cigarette within 30 minutes of waking up.
CHRONO THERAPEUTICS’S WEARABLE DEVICE AIMS TO HELP SMOKERS QUIT
Medical Device and Diagnostic Industry, Jan 14, 2016
The skin patch is an established and proven tool in nicotine replacement therapy, but it still has limitations. Strongest right after it is first applied to the skin, a nicotine patch's waning potency later in the day can lead smokers to relapse.
Hayward, CA-based Chrono Therapeutics is using medical technology to modernize traditional approaches to smoking cessation. The company has developed a way to provide timed transdermal drug delivery via a wearable device.
CHRONO THERAPEUTICS NETS ROCK HEALTH INVESTMENT FOR SMOKING CESSATION WEARABLE
MedCity News, March 3, 2015
Rock Health entered the arena of digital health tools for smoking cessation with an investment in Chrono Therapeutics, according to a company statement. The pharmaceutical company produces a wearable drug delivery tool and companion app called SmartStop, which functions as a digital health coach to help smokers quit. The investment follows a $32 million Series A round in June.
THIS WEARABLE HELPS YOU QUIT SMOKING BY DOSING YOU WITH NICOTINE
WIRED, January 28, 2015
Yes, we already have the nicotine patch and nicotine gum and all sorts of anti-smoking lozenges. But Levy believes we can turn quitting into a more exact science with a wearable device that careful administers nicotine to your particular specifications. ...
9 WEARABLES TOTALLY CHANGING THE MEDICAL INDUSTRY
Brit + Co, December 13, 2014
When someone says "wearables" you naturally think about fitness and health wearables or smart watches. These wearables can relay notifications to you or track your calories burned -- which is cool and all -- but the medical industry has been making their own amazing advancements in ...
MEDTECH WINNERS OF 2014: CLINICAL WEARABLES
Medical Device and Diagnostic Industry, December 9, 2014
Wearables landed on MD+DI's 2013 loser's list largely because of the overwhelming focus of wearables makers to create health and fitness-type consumer devices with scant regard for moving the needle on chronic disease management or in using wearable in a regulated, clinical environment. This year, however, major strides ...
WEARABLES MOVE FROM THE “WORRIED WELL” CONSUMER MARKET TO CLINICAL DOMAIN
Medical Device and Diagnostic Industry, August 12, 2014
The true value of wearable technologies lies in the regulated medical world where it can affect large-scale change, writes Wende Hutton, a West Coase venture capitalist. Thanks Google! With the recent press on Google's new frontier of the human body called the Baseline ...
WEARABLE MAKER CHRONO RAISES $32 MILLION SO SMOKERS CAN KICK THE HABIT
TechCrunch, June 12, 2014
Although the company is launching with a device to treat addiction to smoking, Dr. Levy sees applications that range far beyond kicking the nicotine habit. He says that the company's technology can be used to treat other diseases from addiction to prescription ...
WEARABLE MAKER CHRONO NABS $32M TO HELP SMOKERS QUIT
Silicon Valley Business Journal, June 12, 2014
Canaan general partner Wende Hutton, 5AM's Jim Young and Fountain's Aidan King will join Chrono's board as part of the financing, according to a news release. The capital will allow Chrono Therapeutics to complete development and clinical studies of it's SmartStop device ...
CHRONO RAISES $32M TO MAKE SMART NICOTINE PATCH
FOX Business, June 12, 2014
Like the Fitbit or the Jawbone Up, the newest piece of wearable technology aims to make users healthier. But instead of counting steps, Chrono Therapeutics' SmartStop wearable is intended to help smokers leave cigarettes behind. The SmartStop device can be worn as a watch, an ...
Chrono Therapeutics Announces Appointment of David Happel as Chief Executive Officer – Dr. Alan Levy to Retire as CEO
Feb 1, 2018
Hayward, CA – February 1, 2018 – Chrono Therapeutics, a pioneer in digital drug therapy, today announced that Alan Levy Ph.D., Chief Executive Officer (CEO) and Chairman of the Board of Directors is retiring. David A. Happel has been appointed as the new CEO and current Board member James Young will assume the role of Chairman of the Board. Dr. Levy will continue to serve as a member of the Board.
Chrono Therapeutics Raises $47.6 Million in Series B Financing to advance its clinical platform for personalized drug therapy
Sep 8, 2016
Hayward, CA – September 8, 2016 – Chrono Therapeutics, a pioneer in digital drug therapy and recent recipient of the World Economic Forum Technology Pioneer Award, today announced that it has closed a $47.6 million Series B financing. The round was led by Kaiser Permanente Ventures and included investments by Endeavour Vision, Xeraya Capital Labuan Ltd, Asahi Kasei, Emergent Medical Partners, Hikma Ventures, Cota Capital, and Mission Bay Capital.
CHRONO THERAPEUTICS RECEIVES ISO 13485 CERTIFICATION
Jun 20, 2016
Chrono Therapeutics, a pioneer in digital drug therapy, announced today that its Hayward, California location has received ISO 13485 certification from accredited certification body DEKRA Certification B.V. This certification demonstrates Chrono's commitment to establishing and following policies, practices and procedures to meet the customer, safety and regulatory requirements applicable to medical devices.
ISO 13485 is an International Organization for Standardization (ISO) standard that describes the requirements for a comprehensive quality management ...
CHRONO THERAPEUTICS' smoking cessation technology demonstrates significant reduction in nicotine cravings
Mar 4, 2016
Chrono Therapeutics, a pioneer in digital drug therapy, today announced that clinical data for the company's smoking cessation technology showed a statistically significant reduction in nicotine cravings in a trial of adult male smokers. The data were presented today at the Society for Research on Nicotine & Tobacco's 22nd Annual Meeting. Chrono's wearable transdermal drug delivery device times nicotine delivery to when smokers have their strongest cravings.
CHRONO THERAPEUTICS RECEIVES SECOND FAST TRACK SBIR GRANT FROM NATIONAL CANCER INSTITUTE
Aug 25, 2015
Chrono Therapeutics received a second Phase 1 and Phase 2 Fast Track Small Business Innovation Research (SBIR) grant award from the National Cancer Institute (NCI). This award of up to $2.3 million will support final product development of the digital portion of Chrono's patient-individualized smoking cessation therapy as well as pilot efficacy trials of the system. This is the second Fast Track SBIR grant award Chrono has received from the NCI. Chrono successfully executed on a 2012 $2.23M grant that funded early product engineering and a second in human pharmacokinetic study.
Chrono Therapeutics Recieved Investment from Rock Health to Advance SmartStop™ Smoking Cessation Technology
March 3, 2015
Chrono Therapeutics, a pioneer in digital drug products, today announced an investment by Rock Health, the leading seed fund in digital health, to support the advancement of Chrono’s SmartStop™ programmable transdermal drug delivery system and real-time behavioral support program for smoking cessation...
Chrono Therapeutics, Inventor of Wearable "Smart" Smoking Cessation Technology, Secures $32 Million in Series A Financing
June 12, 2014
Syndicate includes Canaan Partners, 5AM Ventures, Fountain Healthcare Partners, Mayo Clinic and GE Ventures HAYWARD, Calif, June 12, 2014 /PRNewswire/ – Chrono Therapeutics, a pioneer in digital drug products, announced today the close of a $32 million Series A …
New Smoking Cessation Innovation Receives Grant from the National Institute of Health
February 10, 2014
The National Cancer Institute division of the NIH has recently awarded Chrono Therapeutics, a pioneer in digital drug products, a $2.23M grant to commercialize its lead product-SmartStop.™ Smartstop is the first “smart” transdermal nicotine replacement therapy (NRT) system that synchronizes the delivery of …